Clinical trial
A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
NCT02189629 is registered in ClinicalTrials.gov with Galderma R&D as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS
- Lead sponsor
- Galderma R&D
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- February 23, 2015
- Completion date
- February 23, 2017
- Enrollment
- 453 (actual)
- Sites
- 32
Conditions
As the registry lists them; a condition with its own page is linked.